Literature DB >> 28700424

Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics.

Xiaowei Chen1, Rebecca Arend, Diane Hamele-Bena, Ana I Tergas, Melanie Hawver, Guo-Xia Tong, Thomas C Wright, Jason D Wright.   

Abstract

Carcinosarcomas (malignant mixed Müllerian tumors or MMMT) are rare malignant tumors in the female genital tract composed of both malignant epithelial and malignant mesenchymal components. They comprise <5% of all neoplasms in the gynecologic tract and have an aggressive clinical course. The purpose of this study is to evaluate the immunophenotype and possible histogenesis of carcinosarcomas of the uterus. Sixty-two cases of uterine carcinosarcomas diagnosed between 1995 and 2011 were retrieved from the gynecologic pathology files at Columbia University Medical Center. Representative tissue blocks containing both epithelial and mesenchymal components were selected from each case for histologic and immunohistochemical studies. Clinical data from each case were retrieved. The epithelial component was poorly differentiated adenocarcinoma in the majority (80.7%) of cases; in 17.7%, the carcinoma was moderately differentiated, and in only 1.6% the carcinoma was well differentiated. 53% of the tumors had homologous stromal elements and 47% displayed heterologous stromal elements. Immunohistochemical study revealed almost equal staining in both epithelial and mesenchymal components of carcinosarcomas for p16 and p53. PAX8 positivity was noted in 73% of epithelial components, but only 13% of stromal components, and PAX8 stromal positivity was never seen in the absence of PAX8 epithelial positivity. Expression of p16, p53, and PAX8 in both malignant components lends support to the monoclonal theory of uterine carcinosarcoma tumorigenesis. The roles of these tumor markers in the diagnosis and pathogenesis of this tumor and associations between clinical characteristics, tumor pathologic features, and prognosis are discussed.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28700424     DOI: 10.1097/PGP.0000000000000346

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  5 in total

1.  TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma.

Authors:  Antonio Travaglino; Antonio Raffone; Annarita Gencarelli; Antonio Mollo; Maurizio Guida; Luigi Insabato; Angela Santoro; Gian Franco Zannoni; Fulvio Zullo
Journal:  Pathol Oncol Res       Date:  2020-05-29       Impact factor: 3.201

2.  Uterine carcinosarcoma (malignant mixed Müllerian tumor): case report in a goat and literature review.

Authors:  Brieuc Cossic; Jacqueline A Hill; Marta Cercone; Teresa Southard
Journal:  J Vet Diagn Invest       Date:  2018-10-21       Impact factor: 1.279

3.  Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.

Authors:  Ileana C Cuevas; Subhransu S Sahoo; Ashwani Kumar; He Zhang; Jill Westcott; Mitzi Aguilar; Jeremy D Cortez; Stephanie A Sullivan; Chao Xing; D Neil Hayes; Rolf A Brekken; Victoria L Bae-Jump; Diego H Castrillon
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-26       Impact factor: 11.205

4.  Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel.

Authors:  Yusuke Kobayashi; Ikumi Kitazono; Toshiaki Akahane; Shintaro Yanazume; Masaki Kamio; Shinichi Togami; Sachio Nohara; Ippei Sakamoto; Seiya Yokoyama; Kazuhiro Tabata; Hiroaki Kobayashi; Akihide Tanimoto
Journal:  Pathol Oncol Res       Date:  2021-12-23       Impact factor: 3.201

5.  Inter-component immunohistochemical assessment of proliferative markers in uterine carcinosarcoma.

Authors:  Andrzej Pyra; Aneta Adamiak-Godlewska; Dorota Lewkowicz; Beata Bałon; Marek Cybulski; Anna Semczuk-Sikora; Andrzej Semczuk
Journal:  Oncol Lett       Date:  2022-08-31       Impact factor: 3.111

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.